Systemic sclerosis after interferon-alfa therapy for myeloproliferative disorders.
Beretta
L
L
Caronni
M
M
Vanoli
M
M
Scorza
R
R
D000970:Antineoplastic Agents / Q000009:adverse effects*; D005260:Female; D006684:HLA-DR Antigens / Q000032:analysis; D059810:HLA-DR Serological Subtypes; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000009:adverse effects*; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy* / Q000276:immunology; D008875:Middle Aged; D011994:Recombinant Proteins; D012595:Scleroderma, Systemic / Q000209:etiology* / Q000276:immunology
D000970:Antineoplastic Agents; D006684:HLA-DR Antigens; D059810:HLA-DR Serological Subtypes; C080766:HLA-DR11 antigen; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins